Xbrane Biopharma AB (STU:7XB)
€ 0.024 +0.0095 (+66.9%) Market Cap: 39.47 Mil Enterprise Value: 50.63 Mil PE Ratio: 0 PB Ratio: 1.90 GF Score: 54/100
Back to the Transcripts List

Q1 2025 Xbrane Biopharma AB Earnings Call Transcript

May 8, 2025 / 07:00 AM GMT
Release Date Price: €0.0103

Key Points

Positve
  • Xbrane Biopharma AB (FRA:7XB) secured a significant transaction with Albotech, selling its XP03 program and laboratory activities for 275 million Swedish crowns, improving its financial position.
  • The company plans to repay its current debt, including a 150 million Swedish crowns convertible bond, and reduce its fixed cost base to approximately 40 million Swedish crowns annually.
  • Xbrane Biopharma AB (FRA:7XB) reported a strong volume growth of 36% in Q1 2025 for its Lucentis biosimilar, with a profit share of nearly 20 million Swedish crowns.
  • The company has a strategic focus on its Lucentis and Optivo biosimilar candidates, aiming to optimize cash flows and potentially expand its market share.
  • Xbrane Biopharma AB (FRA:7XB) has a promising partnership with Valorum Biologics for the US market, which is valued at $10 billion, and anticipates a significant opportunity upon FDA approval.
Negative
  • The sales ramp-up for the Lucentis biosimilar has been slower than anticipated due to educational activities and the need for a prefilled syringe version.
  • Xbrane Biopharma AB (FRA:7XB) faces cash flow imbalances, requiring careful financial management to balance cash in and out until the launch of new products.
  • The company reported a negative operating cash flow of 69 million Swedish crowns in Q1 2025, mainly due to sales of inventory items and changes in accounts payables and receivables.
  • There is uncertainty regarding the timeline for FDA approval of the Lucentis biosimilar, as additional documentation was requested, delaying the process.
  • Xbrane Biopharma AB (FRA:7XB) needs to secure further financing to support its investment in the Optivo biosimilar program, which requires about 200 million Swedish crowns.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

XBRANE.ST - Xbrane Biopharma AB
Q1 2025 Xbrane Biopharma AB Earnings Call
May 08, 2025 / 07:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to Explain Bharma's presentation in relation to, our financial report first quarter of 2025.

My name is Martin. I'm the CEO CEO of Xpain, and I have with me today Jane, our CFO.

So we will go through an operational update in relation to the quarter.

I'll start with that, and then Jane will take over and go through a financial update, and then we will open up for questions both via Those calling in and also over the chat.

Yeah.

You move on.

So big event during the quarter was our agreement with Albotech to sell one of our programs, XP03, or by similar candidate to SIMsia as well as part of our organization, the part which is engaged in laboratory activities.
Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.